PUBLICATION

Global Business Reports

AUTHORS

Alice Pascoletti, JP Stevenson

Turkey Pharmaceuticals 2015

June 03, 2015

Far less profitable yet far more innovative than its predecessor of ten years ago, the Turkish pharmaceuticals manufacturing industry and its outlook have changed rapidly as a result of policy reforms enacted in 2004. Executed by the Turkish Ministry of Health under the Health Transformation Program, these reforms were, true to the name that encompasses them, transformative. They restructured healthcare financing, broadly increased medical access within the poorest regions of Turkey, and consolidated Turkey’s three systems of social security under one umbrella, the SGK; 99% of Turkey’s population now has medical coverage. Over the last decade, consumer satisfaction with the country’s health care system rose, per capita doctor visits increased, and rates of child and infant mortality fell.

Yet, this expansion of the medical system brought an expansion in public medical expenses, and with it, the creation of a system of cost controls to prevent these expenses from encumbering the public budget. Cost controls have taken two forms: first, a series of direct discounts imposed on domestic manufactures in accordance with the originator status of their product and the availability of comparable products within the market; and second, the introduction of a system of drug-price referencing that sets the price at which the Turkish pharmaceutical manufacturer can sell a product in the domestic market, linking it to the lowest price at which a comparable pharmaceutical product is sold within a basket of European markets.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

Québec and Atlantic Canada Mining 2025

Québec and Atlantic Canada have traversed 2025 in an enviable position. Strong gold prices have buoyed balance sheets and investor sentiment, while global demand for critical minerals keeps the region firmly on the radar of international markets. At the same time, the provinces’ depth of mining expertise – from AI-driven exploration to advanced drilling, blasting, and geophysics – ensures that technological advantage is firmly on their side.

MORE PREVIOUSLY PUBLISHED

MACIG

"Our jurisdictional diversification is certainly a defining characteristic of Thor, but so is the fact that our projects are also diversified by stage of development."

SUBSCRIBE TO OUR NEWSLETTER